May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
Jan Adamowicz, Kajetan Juszczak, Tomasz Drewa
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Pandemic5 Alpha-Reductase InhibitorMedicineReductaseAlpha (finance)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineBiologyEnzymeVirologySurgeryDiseasePatient satisfactionBiochemistryCancerFinasterideOutbreakConstruct validityInfectious disease (medical specialty)ProstateBody Contouring and SurgeryCOVID-19 and healthcare impactsGenital Health and Disease